The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).
Timothy Jay Price
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
Maressa Bruhn
No relevant relationships to disclose
Chee Lee
No relevant relationships to disclose
Jenny Hardingham
Research Funding - Roche
Amanda Rose Townsend
No relevant relationships to disclose
Kristy Mann
No relevant relationships to disclose
John Simes
No relevant relationships to disclose
Andrew James Weickhardt
No relevant relationships to disclose
Joe Wrin
No relevant relationships to disclose
Kate Wilson
No relevant relationships to disclose
Val Gebski
No relevant relationships to disclose
Bridget Anne Robinson
No relevant relationships to disclose
Guy A. Van Hazel
No relevant relationships to disclose
David Cunningham
Research Funding - Roche
Niall C. Tebbutt
Consultant or Advisory Role - Roche (U)